On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management
In 2020, investigators presented the first efficacy results from the phase 3 WSG-ADAPT HR+/HER2- trial in patients with luminal early breast cancer.1 Among patients with up to 2 involved axillary nodes, endocrine therapy (ET) alone produced excellent long-term outcomes for […]
On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management Read More »